Drug Interactions between Gleevec and sunitinib
This report displays the potential drug interactions for the following 2 drugs:
- Gleevec (imatinib)
Interactions between your drugs
There were no interactions found in our database between Gleevec and sunitinib - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
- Gleevec is in the drug class BCR-ABL tyrosine kinase inhibitors.
- Gleevec is used to treat the following conditions:
- Sunitinib is a member of the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors.
- Sunitinib is used to treat the following conditions:
Drug and food interactions
Applies to: Gleevec (imatinib)
Grapefruit juice may increase the blood levels of certain medications such as imatinib. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with imatinib. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.
Applies to: sunitinib
SUNItinib may be taken with or without food. If you are receiving therapy with SUNItinib you should avoid the regular consumption of large amounts of grapefruits and grapefruit juice. Grapefruit can raise the levels of SUNItinib in your body and lead to increased side effects. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.